Top in endocrinology: Next-generation glucose monitor; increase in thyroid cancer
Click Here to Manage Email Alerts
The top story in endocrinology last week was about the FDA’s clearance of the FreeStyle Libre 3 system, a next-generation integrated continuous glucose monitor for patients with diabetes.
According to a press release from the manufacturer, the FreeStyle Libre 3 (Abbott) is the smallest and thinnest sensor developed to date — about the size of two stacked United States pennies. It also improves upon its predecessor’s mean absolute relative difference of 9.3% to 7.9% at 14 days of use, according to the release.
Another top story was about a study that found an increase in thyroid cancer cases in Denmark from 2005 to 2019.
Read these and more top stories in endocrinology below:
FDA clears next-generation FreeStyle Libre 3 CGM for people with diabetes
The FDA has cleared a next-generation integrated continuous glucose monitor for people with diabetes aged 4 years and older, according to a press release from Abbott. Read more.
Thyroid cancer rates on the rise across all income, education levels
Incidences of thyroid cancer increased in Denmark from 2005 to 2019 across all income and education levels, according to study findings published in Thyroid. Read more.
Achieving biomarker goals extends life expectancy in type 2 diabetes
People with type 2 diabetes who achieved recommended targets for HbA1c, systolic blood pressure, LDL cholesterol and BMI had increased life expectancy, although the size of increase differed among the biomarkers, concluded recent research. Read more.
Tele-screening for diabetic retinopathy found feasible, effective
Among diabetes care centers in India, screening for diabetic retinopathy using tele-ophthalmology proved feasible and effective for sight-threatening diabetic retinopathy, according to study results. Read more.
Few adults with type 2 diabetes use SGLT2 inhibitors, GLP-1 receptor agonists
Fewer than one in 10 adults with type 2 diabetes in the U.S. use SGLT2 inhibitors or GLP-1 receptor agonists, and only SGLT2 inhibitors have seen an increase in use over the last decade, according to study findings. Read more.